Patent · US Active

CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

US10975158B2 · kind B2 · utility

2Cited by

18References

13Claims

0Family size

Assignee

The Regents of the University of California · US

Inventor

Sherie L. Morrison · Los Angeles, US

Key dates

Filing date	Oct 20, 2017
Grant date	Apr 13, 2021
Priority date	—
Expiry date	Oct 20, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/74
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.